AEON Biopharma, Inc.
For the period ended Dec 31, 2024. Filed Mar 24, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 24, 2025
AEON$0.18-1.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Financial Statements and Supplementary Data
Index to Consolidated Financial Statements
| | | |
|---|---|---|
| | | |
| Report of Independent Registered Public Accounting Firm (PCAOB ID Number 185) | | 92 |
| | | |
| Consolidated Balance Sheets as of December 31, 2024 (Successor) and December 31, 2023 (Successor) | | 93 |
| | | |
| Consolidated Statements of Operations and Comprehensive Income (Loss) for the year ended December 31, 2024 (Successor) and the periods from January 1, 2023 to July 21, 2023 (Predecessor) and July 22, 2023 to December 31, 2023 (Successor) | | 94 |
| | | |
| Consolidated Statements of Convertible Preferred Stock and Stockholders’ Deficit for the year ended December 31, 2024 (Successor) and the periods from January 1, 2023 to July 21, 2023 (Predecessor) and July 22, 2023 to December 31, 2023 (Successor) | | 95 |
| | | |
| Consolidated Statements of Cash Flows for the year ended December 31, 2024 (Successor) and the periods from January 1, 2023 to July 21, 2023 (Predecessor) and July 22, 2023 to December 31, 2023 (Successor) | | 96 |
| | | |
| Notes to Consolidated Financial Statements | | 97 |
| | | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.